Literature DB >> 10884498

Role of taxoids in head and neck cancer.

D Schrijvers1, J B Vermorken.   

Abstract

Docetaxel and paclitaxel represent a new class of cytotoxic agents having both a specific chemical structure and mechanism of action. They act to promote tubulin polymerization and the formation of stable microtubules. The microtubules produced in the presence of taxoids are resistant to disassembly by physiologic stimuli, and cells exposed to these agents exhibit an accumulation of disorganized microtubule arrays. This affects the normal mitotic process and eventually results in cell death. Both drugs are active as single agents in patients with head and neck cancer with response rates ranging from 20% to 40%. They may be combined with other cytotoxic agents, radiotherapy, or both. A review is given of the presently available data.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884498     DOI: 10.1634/theoncologist.5-3-199

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  13 in total

1.  Synergistic suppression of apoptosis in salivary acinar cells by IGF1 and EGF.

Authors:  K H Limesand; K A Barzen; D O Quissell; S M Anderson
Journal:  Cell Death Differ       Date:  2003-03       Impact factor: 15.828

2.  Combined-modality treatment in advanced oral squamous cell carcinoma: Primary surgery followed by adjuvant concomitant radiochemotherapy.

Authors:  Matthias Kreppel; Uta Drebber; Hans-Theodor Eich; Timo Dreiseidler; Joachim E Zöller; Rolf-Peter Müller; Martin Scheer
Journal:  Strahlenther Onkol       Date:  2011-03-14       Impact factor: 3.621

3.  Long-Term Outcomes of Patients with Squamous Cell Carcinoma of the Temporal Bone after Concomitant Chemoradiotherapy.

Authors:  Kiyoto Shiga; Katsunori Katagiri; Daisuke Saitoh; Takenori Ogawa; Kenjiro Higashi; Hisanori Ariga
Journal:  J Neurol Surg B Skull Base       Date:  2018-05-14

4.  Concomitant chemoradiotherapy as a standard treatment for squamous cell carcinoma of the temporal bone.

Authors:  Kiyoto Shiga; Takenori Ogawa; Atsuko Maki; Masanori Amano; Toshimitsu Kobayashi
Journal:  Skull Base       Date:  2011-05

5.  Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line.

Authors:  Cheng-Zhi Xu; Jin Xie; Bin Jin; Xin-Wei Chen; Zhen-Feng Sun; Bao-Xing Wang; Pin Dong
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

6.  Differential gene expression in a paclitaxel-resistant clone of a head and neck cancer cell line.

Authors:  Marianne Schmidt; Gabriele Schler; Petra Gruensfelder; Florian Hoppe
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-12-28       Impact factor: 2.503

7.  [Survival with distant metastatic disease in head and neck cancer. A retrospective analysis].

Authors:  B Dietl; J Marienhagen; C Schaefer; F Pohl; T Murthum; O Kölbl
Journal:  HNO       Date:  2007-10       Impact factor: 1.284

8.  Feasibility and response of concurrent weekly docetaxel with radical radiotherapy in locally advanced head and neck squamous cell carcinoma.

Authors:  Jomon Raphael C; Rajesh I; Rajesh B; Selvamani B; Subhashini John
Journal:  J Clin Diagn Res       Date:  2015-03-01

9.  Pulmonary toxicity in patients receiving docetaxel chemotherapy.

Authors:  Perran F Yumuk; Umut Kefeli; Berrin Ceyhan; Faysal Dane; Basak T Eroglu; Mahmut Gumus; Devrim Cabuk; Gul Basaran; Ufuk Abacioglu; Nazım S Turhal
Journal:  Med Oncol       Date:  2009-12-25       Impact factor: 3.064

10.  Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis.

Authors:  Hao Qin; Jie Luo; Yuan-Ping Zhu; Hai-Li Xie; Wei-Qiang Yang; Wen-Bin Lei
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.